Immunoglobulin A (IgA) nephropathy, also called Berger’s disease, is an autoimmune disease that affects your kidneys. IgA is an antibody. Antibodies are proteins made by your immune system.

Some people with IgA nephropathy take regular steroids, budesonide (Tarpeyo), or SGLT-2 inhibitors to lower the amount of protein in their urine. Swollen legs and feet. With kidney disease ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Fibroblast activating protein inhibitor (FAPI) PET/CT imaging may be a non-invasive modality to monitor IgA nephropathy (IgAN) progression, preliminary study results suggest.

The biopsy showed that Miller had IgA nephropathy, which was difficult news to receive. “It changed my life quite a bit, as you can imagine, getting a diagnosis for a rare disease that there’s ...

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA ...

Early detection and treatment of IgA nephropathy are critical for better outcomes, but many patients present with advanced kidney disease, often due to a delay in diagnosis. This delay is largely ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease.

The global IgA nephropathy disease treatment market is poised for substantial growth, with projections indicating a robust CAGR of 20.8% during the forecast period from 2022 to 2028. This growth is ...